Louise O'Reilly (Dublin Fingal, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

553. To ask the Minister for Health when a group (details supplied) will be prioritised for the Covid-19 vaccination. [54011/21]

Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

The immunisation programme in Ireland is based on the advice of the National Immunisation Advisory Committee (NIAC). The Committee reviews data relating to Covid-19 vaccines on a rolling basis and makes recommendations on vaccination policy to my Department.

Following the recommendation for use of vaccines against COVID-19 by the European Medicines Agency (EMA) and authorisation for use by the European Commission, the NIAC develops guidance for their use in Ireland which is contained in the Immunisation Guidelines for Ireland. These guidelines are continuously updated and include guidance on all new vaccines as they are approved for use in Ireland.

You can read the guidelines at: www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/covid19.pdf

On the 28th of May, the EMA recommended an extension of the use of the Pfizer vaccine to include those aged 12 to 15 years. The EMA subsequently advised an extension of indication for the Moderna vaccine to include use in children aged 12-17 years. The NIAC reviewed these findings and has recommended that vaccination be extended to those aged 12 -15 years, those in this age group will be offered an mRNA vaccination to protect themselves from COVID-19. There are currently no vaccines authorised for use for those aged under 12 years old.

Clinical trials to assess the safety and effectiveness of COVID-19 vaccines in children under 12 years of age are currently ongoing, with results expected later this year. Vaccine manufacturers Pfizer and Moderna are conducting trials in healthy children between the ages of 6 months and 11 years old using lower vaccine doses. Children have different reactions to medications and vaccinations, so conducting clinical trials specific to that population is important to fully understand the benefits and potential side effects of COVID-19 vaccines in this group. Once the data becomes available, it will be thoroughly reviewed by the EMA and the NIAC prior to the vaccines being administered to children under age 12.